Intravesical Injection of Botox for Treating Therapy Refractory Overactive Bladder in Females

University of Zurich (UZH)

Status: Completed

Conditions: Overactive Bladder Syndrome

Study type: Observational

Funder types: Other

Identifiers

NCT01042119

FHKUSZ15-2009

Details and patient eligibility

About

The neurotoxin Botox (botulinum neurotoxin type A) is shown to be effective in the treatment of therapy refractory overactive bladder syndrome. Our data suggests a longer during efficacy than known from the use in striated muscle.

The aim of our study is to analyze short- and longterm efficacy after Botox treatment and to evaluate risk factors for non-responders and side effects such as urinary retention.

Enrollment: 200 estimated patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• intravesical treatment with Botox at our clinic

Trial design

200 participants in 1 patient group

Botox

Description:

patients who received intravesical injections of botulinum neurotoxin type A